Iceotope | $26,000,000 | (May 15, 2026)
Wirestock | $23,000,000 | (May 15, 2026)
Graphon AI | $8,300,000 | (May 15, 2026) Certified by Founder
Lodge
Wugen
start up
United States
- St Louis, Missouri
- 17/03/2022
- Unknown
- $200,000,000
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.
Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
- Industry Biotechnology
- Website https://www.wugen.com/
- LinkedIn https://www.linkedin.com/company/wugen/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Ranger AI | $8,400,000 | (May 15, 2026)
Chromie Health | $2,000,000 | (May 15, 2026)
Origin Lab | $8,000,000 | (May 14, 2026)
Synthetic | $10,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Dolfin | $2,460,580 | (May 14, 2026)
Data Mission | $1,000,000 | (May 14, 2026)
Urologic Health | $11,000,000 | (May 14, 2026)